Midatech Pharma PLC Publication of Annual Report (5637R)

TIDMMTPH

RNS Number : 5637R

Midatech Pharma PLC

30 June 2020

30 June 2020

Midatech Pharma PLC

("Midatech" or the "Company")

Publication of Annual Report

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines announces that electronic copies of its Annual Report and Accounts for the year ended 31 December 2019 are now available from the Company's investor relations website at http://www.midatechpharma.com/ . Hard copies of the 2019 Annual Report and Accounts are expected to be posted to shareholders shortly.

For more information, please contact:

 
  Midatech Pharma PLC 
  Stephen Stamp, CEO, CFO 
  Tel: [phone] 
   www.midatechpharma.com 
 
  Panmure Gordon (UK) Limited (Nominated Adviser and Broker) 
  Freddy Crossley, Emma Earl (Corporate Finance) 
  James Stearns (Corporate Broking) 
 
  Turner Pope Investments (TPI) Limited (Joint Broker) 
  Andrew Thacker (Corporate Broking) 
  Tel: [phone] 
  IFC Advisory Limited (Financial PR and UK Investor Relations) 
  Tim Metcalfe / Graham Herring 
  Tel: [phone] 
  Email: [e-mail] 
 
  Edison Group (US Investor Relations) 
   Joseph Green/ Laine Yonker 
   Tel: [phone] 
   [e-mail]/[e-mail] 
 

About Midatech Pharma PLC

Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on 'Making Medicines Better' by improving delivery of drugs in the body. The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment for life threatening diseases.

The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

 
  --  Q-Sphera(TM) platform: a disruptive micro-technology used for sustained release to prolong 
       and control the release of therapeutics over an extended period of time (from weeks to months). 
  --  MidaSolve(TM) platform: an innovative nano-technology used to dissolve insoluble drugs so 
       that they can be administered in liquid form directly and locally into tumours. 
 
 
  --  MidaCore(TM) platform: a leading edge nano-technology used for targeting medications to sites 
       of disease. 
 

By improving biodelivery and biodistribution of approved existing molecules, Midatech's unique R&D has the potential to make medicines better, lower technical risks, accelerate regulatory approval and route to market, and provide newly patentable products. The platform nature of the technologies allows the potential to develop multiple drug assets rather than being reliant on a limited number of programmes.

Midatech's headquarters and R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

ACSFZGFVZGDGGZM

(END) Dow Jones Newswires

June 30, 2020 08:37 ET (12:37 GMT)